Floatz logo

Anti-Cd19 Car-Nk Cells

Refractory/Recurrent Central Nervous System Lymphoma

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

73 Active assets in the Refractory/Recurrent Central Nervous System Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
(+)-VINCRISTINE
Ono Pharmaceutical Co., Ltd.
Phase 4BBB
METHOTREXATE
Assistance Publique Hopitaux De Marseille
Phase 4BB
Orelabrutinib
The First Affiliated Hospital with Nanjing Medical University
Phase 3BB
Inno-206
Juan P. Alderuccio, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Anti-Cd19 Car-Nk Cells is also rated in:

B-cell prolymphocytic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →